ABIVAX vs Bausch + Lomb
ABIVAX (ABVX), health care, and Bausch + Lomb (BLCO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Bausch + Lomb is worth $7.4B on the stock market and ABIVAX $7.2B: Bausch + Lomb is valued at 4% more. Over the past year ABIVAX's share price has moved -26.5% and Bausch + Lomb's +38.3%.
Key facts
- ABIVAX market value
- $7.2B
- Bausch + Lomb market value
- $7.4B
- Bausch + Lomb revenue
- $5.1BFY to 2025-12-31
- Superinvestors holding both
- 0
Market values as of .
| Measure | ABIVAX | Bausch + Lomb |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $7.2Blower | $7.4Bhigher |
| Revenue | — | $5.1B |
| Earnings | -$372.9Mlower | -$360Mhigher |
| Employees | 98lower | 13,000higher |
| Total assets | $648.3Mlower | $14Bhigher |
| Valuation | ||
| P/E | — | — |
| P/S | — | 1.5 |
| P/B | — | — |
| Dividend yield | — | — |
| Profitability | ||
| Operating margin | — | 2.22% |
| Balance sheet | ||
| Net assets | $505.1Mlower | $6.4Bhigher |
| Total liabilities | $143.3Mlower | $7.5Bhigher |
| Total debt | — | $5B |
| Cash on hand | $573.3Mhigher | $383Mlower |
| Price change | ||
| Today | -1.81%lower | -0.24%higher |
| 1 year | -26.5%lower | +38.3%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (0)
None of the tracked investors.
ABIVAX only (4)
- Peter Kolchinsky1.3%
- Doug Silverman0.4%
- Andrew Spokes0.1%
- Lee Ainslie<0.1%
Bausch + Lomb only (4)
- Howard Marks1.1%
- Larry Robbins0.6%
- Carl Icahn0.4%
- Dan Loeb<0.1%
Percentages are each holding's share of that investor's reported portfolio. Who owns ABVX · Who owns BLCO
More on ABIVAX
Further comparisons
ABIVAX against its closest peers
Bausch + Lomb against its closest peers
Learn
Questions and answers
Which is bigger, ABIVAX or Bausch + Lomb?
By market value, Bausch + Lomb is the larger: $7.4B against $7.2B for ABIVAX.
Which superinvestors own both ABIVAX and Bausch + Lomb?
None of the tracked superinvestors holds both in their latest 13F filing. 4 hold ABIVAX and 4 hold Bausch + Lomb.
Cite this page
Funkfolio, “ABIVAX vs Bausch + Lomb”, data as of 17 November 2026. https://funkfolio.com/compare/abvx-vs-blco
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.